The Glimpse Group Awarded NIH Grant - In Partnership With Yale, Drexel University and New Jersey Institute of Technology (NJIT) - To Advance Virtual Reality Education for Adolescent and Young Adult Cancer Patients
The Glimpse Group (NASDAQ:VRAR), an Immersive Technology platform company, has secured a significant NIH Small Business Technology Transfer (STTR) grant in collaboration with Yale School of Medicine, Drexel University, and NJIT. The mid-six figure project, titled "Life at 100.4," aims to develop a VR-based educational program for adolescent and young adult cancer patients.
The initiative focuses on addressing febrile neutropenia, a potentially life-threatening complication affecting cancer patients. The program will serve the approximately 90,000 adolescents and young adults diagnosed with cancer annually in the United States, utilizing virtual reality technology to enhance patient education and healthcare navigation.
The Glimpse Group (NASDAQ:VRAR), una piattaforma di tecnologia immersiva, ha ottenuto un significativo contributo NIH STTR (Small Business Technology Transfer) in collaborazione con la Yale School of Medicine, la Drexel University e il NJIT. Il progetto a cifra media di sei zeri, intitolato "Life at 100.4,", mira a sviluppare un programma educativo basato su VR per adolescenti e giovani adulti con cancro.
L’iniziativa si concentra sull’individuazione e gestione della neutropenia febbrile, una complicanza potenzialmente letale che colpisce i pazienti oncologici. Il programma servirà circa 90.000 adolescenti e giovani adulti diagnosticati con cancro ogni anno negli Stati Uniti, utilizzando la tecnologia di realtà virtuale per migliorare l’educazione dei pazienti e la navigazione nell’assistenza sanitaria.
The Glimpse Group (NASDAQ:VRAR), una plataforma de tecnología inmersiva, ha obtenido una importante -subvención STTR de la NIH (Small Business Technology Transfer) en colaboración con la Yale School of Medicine, la Drexel University y el NJIT. El proyecto de seis cifras medias, titulado "Life at 100.4", tiene como objetivo desarrollar un programa educativo basado en VR para pacientes adolescentes y jóvenes adultos con cáncer.
La iniciativa se centra en abordar la neutropenia febril, una complicación potencialmente mortal que afecta a pacientes con cáncer. El programa atenderá a aproximadamente 90,000 adolescentes y jóvenes adultos diagnosticados con cáncer cada año en los Estados Unidos, utilizando la tecnología de realidad virtual para mejorar la educación de los pacientes y la navegación en la atención médica.
The Glimpse Group (NASDAQ:VRAR), 몰입형 기술 플랫폼 기업은 Yale School of Medicine, Drexel University 및 NJIT와 협력하여 중요한 NIH 소기업 기술 이전(STTR) 보조금을 확보했습니다. 중간 6자리 수 프로젝트로 제목은 "Life at 100.4"이며 청소년 및 청년 암 환자를 위한 VR 기반 교육 프로그램 개발을 목표로 합니다.
이 이니셔티브는 암 환자에게 영향을 미치는 생명에 위협이 될 수 있는 발열성 호중구감소증(neutropenia)을 다루는 데 중점을 두고 있습니다. 이 프로그램은 미국에서 매년 약 90,000명의 암으로 진단된 청소년 및 청년 성인에게 서비스를 제공하며, 환자 교육과 의료 탐색을 향상시키기 위해 가상현실 기술을 활용합니다.
The Glimpse Group (NASDAQ:VRAR), une plateforme de technologies immersives, a obtenu une importante bourse STTR de la NIH (Small Business Technology Transfer) en collaboration avec la Yale School of Medicine, Drexel University et NJIT. Le projet à revenu moyen à six chiffres, intitulé "Life at 100.4", vise à développer un programme éducatif basé sur la réalité virtuelle pour les adolescents et les jeunes adultes atteints de cancer.
L’initiative se concentre sur le traitement de la neutropénie fébrile, une complication potentiellement mortelle chez les patients atteints de cancer. Le programme desservira environ 90 000 adolescents et jeunes adultes diagnostiqués d’un cancer chaque année aux États‑Unis, en utilisant la technologie de réalité virtuelle pour améliorer l’éducation des patients et l’orientation dans le système de soins.
The Glimpse Group (NASDAQ:VRAR), ein Plattformunternehmen für immersive Technologie, hat von Yale School of Medicine, Drexel University und NJIT in Zusammenarbeit einen bedeutenden NIH STTR-Zuschuss (Small Business Technology Transfer) erhalten. Das Projekt mit mittleren sechsstelligen Beträgen, betitelt "Life at 100.4," zielt darauf ab, ein VR-basiertes Bildungsprogramm für jugendliche und junge erwachsene Krebs-Patienten zu entwickeln.
Die Initiative konzentriert sich darauf, die febrile Neutropenie zu adressieren, eine potenziell lebensbedrohliche Komplikation bei Krebspatienten. Das Programm wird etwa 90.000 Jugendliche und junge Erwachsene, die jährlich mit Krebs diagnostiziert werden, in den USA bedienen und Virtual-Reality-Technologie nutzen, um die Patientenaufklärung und die Navigation im Gesundheitswesen zu verbessern.
The Glimpse Group (NASDAQ:VRAR)، وهي شركة منصة تكنولوجيا غامرة، حصلت على منحة بارزة من NIH Small Business Technology Transfer (STTR) بالتعاون مع Yale School of Medicine وDrexel University وNJIT. المشروع ذو قيمة ثلاثية إلى الستة أرقام، بعنوان "Life at 100.4"، يهدف إلى تطوير برنامج تعليمي قائم على الواقع الافتراضي للمرضى من المراهقين والشباب المصابين بالسرطان.
تركّز المبادرة على معالجة نقص العدلات المصحوب بالحمّى، وهو مضاعفة قد تهدد حياة مرضى السرطان. سيخدم البرنامج حوالي 90,000 مراهق وشاب يُشخّصون بالسرطان سنوياً في الولايات المتحدة، باستخدام تقنيات الواقع الافتراضي لتعزيز تعليم المرضى وتوجيه الرعاية الصحية.
The Glimpse Group (NASDAQ:VRAR)，一家沉浸式技术平台公司，已与耶鲁医学院、德雷塞尔大学和新泽西理工学院合作，获得了一项重要的 NIH 小型企业技术转让(STTR) 资助。该中等六位数的项目，题为“Life at 100.4”，旨在开发一个 基于VR的教育项目，面向青少年和年轻成年人癌症患者。
该计划重点解决发热性中性粒细胞减少症，这是一种可能威胁生命的并发症。该项目将为美国约 每年诊断出癌症的青少年和年轻成年人约90,000名患者提供服务，利用虚拟现实技术提升患者教育和医疗导航。
- Secured prestigious NIH grant with mid-six figure funding
- Strategic partnerships with major institutions: Yale, Drexel, and NJIT
- Addresses large market of 90,000 annual young cancer patients in the US
- Strengthens company's position in healthcare VR applications
- None.
Insights
NIH grant validates Glimpse's VR technology in healthcare education, strengthening institutional partnerships while having minimal immediate revenue impact.
The mid-six figure NIH grant awarded to Glimpse Group represents a strategic validation of virtual reality's application in specialized healthcare education. This STTR (Small Business Technology Transfer) project focuses on developing VR tools to educate young cancer patients about febrile neutropenia - a potentially life-threatening complication affecting the 90,000 adolescents and young adults diagnosed with cancer annually in the US.
While the direct financial impact is modest relative to typical public company revenues, the grant's true value lies in its institutional validation and partnership framework. Collaboration with Yale School of Medicine, Drexel University, and NJIT significantly enhances Glimpse's credibility in the healthcare education sector, potentially opening doors to larger medical training applications and future NIH funding.
The project strategically positions Glimpse in the intersection of several high-growth markets: healthcare education, oncology support services, and digital therapeutics. The company is leveraging its immersive technology expertise to address a specific clinical need with strong medical justification - reducing treatment complications through improved patient education.
From a product development perspective, this initiative creates a reusable framework for condition-specific VR education modules that could be expanded to other medical conditions or training scenarios, potentially establishing a blueprint for future commercialization in healthcare education.
NEW YORK, NY / ACCESS Newswire / September 16, 2025 / The Glimpse Group, Inc. ("Glimpse") (NASDAQ:VRAR), a diversified Immersive Technology platform company providing enterprise-focused Immersive Technology, Spatial Computing and Artificial Intelligence ("AI") driven software and services, today announced that is was awarded a prestigious, Small Business Technology Transfer (STTR) grant from the National Institute of Nursing Research at the National Institutes of Health (NIH), in partnership with Yale School of Medicine (YSM), Drexel University, and New Jersey Institute of Technology (NJIT).
The mid-six figure dollar project, "Life at 100.4: An Immersive Social Virtual Reality Education Tool for Adolescent and Young Adult Cancer Patients and Caregivers," will develop and evaluate an immersive VR-based program designed to improve patient understanding and management of febrile neutropenia during cancer treatment.
Nearly 90,000 adolescents and young adults are diagnosed with cancer each year in the United States. Febrile neutropenia, a dangerous complication of treatment, can be life-threatening if not addressed quickly. This initiative leverages cutting-edge virtual reality technology to provide engaging, evidence-based education for patients and caregivers, helping them recognize symptoms early and navigate the healthcare system effectively.
Dr. Asher Marks, Yale School of Medicine (Principal Investigator), commented: "Adolescents and young adults with cancer face unique challenges, and delays in care can have devastating consequences. By using immersive VR experiences, we aim to bridge knowledge gaps, improve health literacy, and ultimately save lives. This project represents a critical step in using digital innovation to empower patients and caregivers."
DJ Smith, Chief Creative Officer, The Glimpse Group (Co-Investigator), commented: "At Glimpse, we've seen the transformative potential of VR across industries, and healthcare is one of the most impactful areas. Partnering with YSM, Drexel, and NJIT allows us to bring together world-class medical expertise, immersive technology, and design innovation to tackle one of the most urgent problems in oncology care."
Dr. Frank Lee, Professor, Drexel University (Co-Investigator), commented: "Drexel's long-standing leadership in immersive technology research and game-based learning makes this collaboration especially exciting. By combining our expertise with Glimpse, YSM, and NJIT, we are building a model of how cross-institutional innovation can directly improve patient outcomes."
Acknowledgment of NIH Support
Research reported in this press release was supported by the National Institute of Nursing Research of the National Institutes of Health under Award Number R41NR022239.
About The Glimpse Group, Inc.
The Glimpse Group (NASDAQ: VRAR) is a diversified Immersive technology platform company, providing enterprise-focused Immersive Technology, Spatial Computing and AI driven software & services. Glimpse's unique business model builds scale and a robust ecosystem, while simultaneously providing investors an opportunity to invest directly into this emerging industry via a diversified platform. For more information on The Glimpse Group, please visit www.theglimpsegroup.com
Safe Harbor Statement
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. This press release may contain certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements, if provided, are based on information available to the Company as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business. Forward-looking statements, if provided, include statements regarding our expectations, beliefs, intentions, or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "view," "could," "estimate," "expect," "intend," "may," "should," and "would" or similar words. All forecasts, if provided, are based on information available at this time and management expects that internal projections and expectations may change over time. In addition, any forecasts, if provided, are entirely on management's best estimate of our future financial performance given our current contracts, current backlog of opportunities and conversations with new and existing customers about our products and services. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise.
Glimpse Contacts:
DJ Smith
Chief Creative Officer
dj@glimpsegroup.io
Maydan Rothblum
CFO & COO
The Glimpse Group, Inc.
917-292-2685
maydan@theglimpsegroup.com
SOURCE: The Glimpse Group, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the purpose of The Glimpse Group's NIH-funded VR project?
How much funding did The Glimpse Group (NASDAQ:VRAR) receive from the NIH grant?
Who are The Glimpse Group's partners in the NIH-funded VR project?
What market size will The Glimpse Group's VR cancer education program address?
What specific medical condition does the VRAR VR education program target?
